Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

Asthma Clinical Trial

Official title:

Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01617746
• Other study ID #: AR012
• Status: Not yet recruiting
• Phase: Phase 2
• First received: March 7, 2012
• Last updated: June 10, 2012
• Start date: November 2012
• Est. completion date: December 2015

Study information

• Verified date: June 2012
• Source: University of Glasgow
• Contact: Mark Spears, MBChB PhD
• Phone: 0141 211 1673
• Email: mark.spears[@]glasgow.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study will be to determine if blockade of endothelin 1 signalling via endothelin receptor A using ambrisentan or dual blockade (A&B) via bosentan can provide protection against methacholine induced bronchoconstriction in asthma.

Description:

Endothelin 1 may have a role in the development of acute airway narrowing in asthma. Blockade of the endothelin system may thereby protect against airway narrowing. Two receptors exist for endothelin 1, Endothelin A & B. Both can be blocked by Bosentan, and the A receptor by ambrisentan. Both medications are currently in use for the treatment of pulmonary arterial hypertension. The investigators will endeavour to examine the potential role of endothelin 1 in the development of airway narrowing in asthma through blockade of the endothelin receptors A&B through the use of bosentan and ambrisentan.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 18
• Est. completion date: December 2015
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Physician diagnosis of asthma confirmed objectively by airway hyperactivity to methacholine (as determined by a = 20% drop in FEV at a methacholine dose of = 8mg/ml after ß-agonist withdrawal as per ATS guidelines)

2. Age range 18-60 years

3. FEV1 = 60% predicted

4. Duration of asthma > 6 months and on stable medication for 4 weeks

5. Prescribed and compliant with inhaled corticosteroid up to a maximum of 2000mcg beclomethasone or equivalent

6. No history of previous regular smoking and current non-smoker

Exclusion Criteria:

1. Unstable asthma; defined as the presence of 1 or more of the following events in the month prior to study [Emergency/'out of hours' visit to GP for asthma exacerbation; GP visit to patient at home for asthma exacerbation or A & E/hospital admission for asthma exacerbation]

2. Treatment with oral corticosteroids in the past month

3. Need for maintenance oral corticosteroid therapy

4. Pregnancy or planning to become pregnant over course of study and up to one month after

5. Excessive risk of hepatotoxicity from endothelin receptor antagonists;

• Alcohol excess (defined as regular consumption above government daily recommend limits; currently defined as 28 units per wk for men, 21 units per week for women)

• Previous intravenous drug use

• Current or known history of liver disease (with the exception of Gilberts disease and gallstones)

• Chronic hepatitis (either viral (e.g. hepatitis B or C) or autoimmune)

• Bilirubin, alanine aminotransferase (ALT) or asparate aminotransferase (AST) greater than the upper limit of normal at screening

6. Anaemia (defined as haemoglobin below the lower reference range for sex) at screening

7. Renal failure (defined as eGFR less than 50 mL/minute/1.73 m2) at screening

8. Known HIV positivity

9. History of inability to tolerate bosentan or ambrisentan

10. Significant medical conditions other than asthma felt by investigator to preclude participation in study. This could be either in patients best interest or due to potential to significantly alter responses to medication and hence alter power of clinical trial (examples include; significant heart failure (NYHA grades II-IV), diabetes mellitus, bronchiectasis or haematological malignancy).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Ambrisentan
5mg od two weeks
• Bosentan
62.5mg bd two weeks
• Placebo
bd for two weeks

Locations

Country	Name	City	State
United Kingdom	Asthma Research Unit, University of Glasgow	Glasgow

Sponsors (2)

Lead Sponsor	Collaborator
University of Glasgow	NHS Greater Glasgow and Clyde

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in doubling dose of methacholine to produce bronchoconstriction compared to placebo	Both active treatments will be compared against placebo with respect to protection against methacholine induced bronchoconstriction	2 weeks	No
Secondary	Which of the endothelin receptors A&B are most bronchoprotective against methacholine	Both bostentan and ambrisentans effect on airway response to methacholine will be compared to placebo. The relative efficacy will be compared, in terms of doubling doses of methacholine.	2 weeks	No